
denis Moro-Sibilot
@dmslung
Professor of Respiratory Medicine, CHU Grenoble-Alpes. Honorary president IFCT Intergroupe Francophone de Cancérologie Thoracique. My opinions are my own.
ID: 1272759720
https://orcid.org/0000-0001-6776-8610 16-03-2013 16:45:21
4,4K Tweet
1,1K Followers
337 Following

The phase III ETOP 25-23 ADOPT-lung will try to determine the benefit of adjuvant immunotherapy after neoadjuvant chemo-IO, outlined in Lung Cancer Journal. Pts with resectable stage IIA-IIIB NSCLC receive induction durvalumab + chemo, then randomized to 1y of durva vs observation.




ESMO has updated it’s living guidelines for oncogene addicted NSCLC #LCSM doi.org/10.1016/j.anno… d.planchard Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Benjamin Besse Sanjay Popat Giannis Mountzios Fred R. Hirsch Suresh S. Ramalingam, MD, FASCO Christine Lovly, MD, PhD, FASCO Hossein Borghaei, DO Joshua Reuss Chul Kim Biagio Ricciuti, MD, PhD Aakash Desai, MD, MPH, FASCO




💡First patient treated by #ivonescimab at CHU de Montpellier in the IFCT-2403 BI-MAPS academic trial dedicated to pleural #mesothelioma @ponstostivint Scherpereel Arnaud iMig 2025 ifct.fr/etudes-cliniqu…

Panel and video highlights from #ASCO25 now available from high5md with Drs. Noemi Reguart Hossein Borghaei, DO Nicolas Girard Frank Griesinger Dr Riyaz Shah Martin Reck Lizza Hendriks and more!


Analysis of MARIPOSA JTO & JTO CRR comparing 1L lazertinib and osimertinib in #EGFR NSCLC. PFS 18.5m with lazertinib vs 16.6m with osimertinib (HR 0.98), RR 83% vs 85%, DOR 16.6m vs 16.8m, OS HR 1.00 - similar tox (laz more rash, osi more diarrhea). jto.org/article/S1556-…

❄️Winter of cancer immunotherapy is here. 𝐀𝐥𝐥-𝐜𝐨𝐦𝐞𝐫𝐬 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 & 𝐍𝐞𝐭𝐰𝐨𝐫𝐤-𝐞𝐟𝐟𝐞𝐜𝐭 slowed progress-we’ve hit a plateau. Time to prioritize innovation over convention! Editorial out in JTO & JTO CRR bit.ly/4eEVcv4 Fabio Salomone Antonio Nuccio


David Gandara Agree - more similar than different. Slightly different toxicity profile and may vary at an individual patient level. But no meaningful differences in efficacy in my opinion. But I do think that Coke >>> Pepsi...




Félicitations au Pr Alexis Cortot Alexis_Cortot , élu Président de l'IFCT (2025-2027), ainsi qu'aux membres élus au Conseil d'Administration de l'IFCT. Merci au Pr Westeel & aux membres sortants pour leur implication dans l’essor de notre intergroupe : ifct.fr/component/acym…



Very important adjustment to FLAURA2 reimbursement in NHS England ; allowing early initiation of TKI while the chemo gets set up. Brilliant initiative by the cancer drugs fund team. BTOG #EGFR EGFR Positive Lung Cancer UK




Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [Jul 20, 2021] Ben Westphalen et al. npj Journals Precision Oncology ow.ly/jDyt50FDVB0 #PrecisionMedicine #RWD #openaccess FoundationCORE® database of >295,000 cancer patients
![Mike Thompson, MD, PhD, FASCO (@mtmdphd) on Twitter photo Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [Jul 20, 2021] <a href="/BenWestphalen/">Ben Westphalen</a> et al. <a href="/Nature_NPJ/">npj Journals</a> Precision Oncology ow.ly/jDyt50FDVB0 #PrecisionMedicine #RWD #openaccess FoundationCORE® database of >295,000 cancer patients Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [Jul 20, 2021] <a href="/BenWestphalen/">Ben Westphalen</a> et al. <a href="/Nature_NPJ/">npj Journals</a> Precision Oncology ow.ly/jDyt50FDVB0 #PrecisionMedicine #RWD #openaccess FoundationCORE® database of >295,000 cancer patients](https://pbs.twimg.com/media/GwfJDwuXUAsVUeH.jpg)